与GAD65抗体相关的神经疾病中的早期神经轴突损伤
Katharina Eisenhut1, Jennifer Faber1, Daniel Engels1
1From the Institute of Clinical Neuroimmunology (K.E.), University Hospital, Ludwig-Maximilians-Universität Munich; Biomedical Center (BMC), Medical Faculty, Ludwig-Maximilians-Universität Munich, Martinsried; Graduate School of Sy; German Center for Neurodegenerative Diseases (DZNE) (J.F.); Department of Neurology, University Hospital Bonn, Germany; Institute of Clinical Neuroimmunology (D.E., R.G., T.K.), University Hospital, Ludwig-Maximilians-Universität Munich; Biomedical Center (BMC), Medical Faculty, Ludwig-Maximilians-Universität Munich, Martinsried; Department of Neurology (J.L.), Ulm University; Department of Neurology (K.D., C.S.), University Hospital Würzburg; Institute of Clinical Chemistry (R.M.), University Hospital Schleswig-Holstein, Lübeck; Institute of Clinical Chemistry (K.K.F.), University Hospital Schleswig-Holstein, Kiel; Department of Neurology and Experimental Neurology (R.R., H.P.), Charité - Universitätsmedizin Berlin; German Center for Neurodegenerative Diseases (DZNE) Berlin; Department of Neurology and Experimental Neurology (C.F.), Charité - Universitätsmedizin Berlin; Section of Translational Neuroimmunology (J.W., C.G.), Department of Neurology, Jena University Hospital; Department of Neurology (D.R.), Hannover Medical School; Institute of Neuroimmunology and Multiple Sclerosis (L.K.P.), Center for Molecular Neurobiology Hamburg, University Medical Center Hamburg-Eppendorf; Department of Neurology (S.B., J.P.), University Medical Center of the Johannes Gutenberg University Mainz; Department of Neurology (A.K.), Martha-Maria Hospital Halle; Department of Neurology (J.K.), University Hospital Bochum; German Center for Neurodegenerative Diseases (DZNE) (B.N.), Munich; Metabolic Biochemistry, Faculty of Medicine, Biomedical Center (BMC), Ludwig-Maximilians-Universität München; and Institute of Clinical Neuroimmunology (F.S.T.), University Hospital, Ludwig-Maximilians-Universität Munich; Biomedical Center (BMC), Medical Faculty, Ludwig-Maximilians-Universität Munich, Martinsried, Germany; Munich Cluster for Sys.
神经轴突损伤发生在谷氨酸脱酶65 (GAD65) 抗体疾病的早期,由血清神经丝光链 (sNfL) 水平升高表明. 早期干预对于这些与GAD65抗体相关的神经疾病至关重要.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 神经科学是一个神经科学.
背景情况:
- 抗谷氨酸脱酶65 (GAD65) 的抗体与各种神经系统疾病有关.
- 神经退行是这些GAD65抗体相关疾病的关键病理特征.
研究的目的:
- 为了研究GAD65抗体相关的神经系统疾病中的神经轴突损伤替代物.
- 为了将神经轴损伤与疾病持续时间和临床表现相关联.
主要方法:
- 研究了50名患有GAD65抗体的多中心队列.
- 测量了血清神经纤维光链 (sNfL) 的水平.
- 分析了自动化MRI体积和临床特征.
主要成果:
- 在病程早期检测到高的sNfL水平,随着疾病持续时间的延长而下降.
- 增加的sNfL水平与小脑缩症和边缘脑炎有关,但不是的人综合征.
- 核磁共振扫描显示大脑小皮层,上后叶和脑皮层在各类表型中都存在主导性缩.
结论:
- 数据表明GAD65抗体相关的神经系统疾病中早期的神经轴损伤.
- 及时的治疗干预得到了早期损伤的发现的支持.
相关概念视频
Botulism
Encephalitis ll: Pathophysiology
Cerebral Edema ll: Pathophysiology
Hepatic Encephalopathy
Secondary Spinal Cord Injury llI: Pathophysiology


